Neuroimaging of Parkinson's disease: Expanding views

Neuroscience and Biobehavioral Reviews

Volumn 59, Issue , 2015, Pages 16-52

  Weingarten, Carol P ^a   Sundman, Mark H ^b   Hickey, Patrick ^a   Chen, Nan kuei ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain imaging; Diffusion tensor imaging; DTI; FMRI; Functional connectivity; Magnetic resonance imaging; MEG; MRI; MRS; Neuroimaging; Parkinson's disease; PET; Positron emission tomography; SPECT; TCS

Indexed keywords

2 [1 [6 [(2 FLUOROETHYL) (METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE F 18; 3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLTHIO)BENZONITRILE C 11; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; CYSTEINE ETHYL ESTER TC 99M; DOPAMINE; DYNORPHIN; ENKEPHALIN; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE F 18; IOFLUPANE I 123; LEVODOPA; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NORADRENALIN; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SUBSTANCE P; UNCLASSIFIED DRUG; WATER O 15; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ALZHEIMER DISEASE; BRAIN DEPTH STIMULATION; CAPSULA INTERNA; CAUDATE NUCLEUS; COMORBIDITY; DEFAULT MODE NETWORK; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOBUS PALLIDUS; HUMAN; MAGNETOENCEPHALOGRAPHY; META ANALYSIS (TOPIC); MOLECULAR IMAGING; MULTIMODAL IMAGING; NEUROIMAGING; NEUROTRANSMISSION; NUCLEUS ACCUMBENS; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; SUSCEPTIBILITY WEIGHTED IMAGING; VENTRAL STRIATUM; ANIMAL; BRAIN; METABOLISM; NERVE CELL NETWORK; PATHOLOGY; PROCEDURES;

ANIMALS; BRAIN; HUMANS; MAGNETOENCEPHALOGRAPHY; NERVE NET; NEUROIMAGING; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE;

EID: 84952038213     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.09.007     Document Type: Review

References (331)

1. Abhinav K., Yeh F.-C., Pathak S., Suski V., Lacomis D., Friedlander R.M., Fernandez-Miranda J.C. Advanced diffusion MRI fiber tracking in neurosurgical and neurodegenerative disorders and neuroanatomical studies: a review. Biochim. Biophys. Acta 2014, 1842:2286-2297.
2. Adler C.H., Beach T.G., Hentz J.G., Shill H.A., Caviness J.N., Driver-Dunckley E., Dugger B.N. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014, 83:406-412.
3. **Agosta F., Canu E., Stefanova E., Sarro L., Tomic A., Spica V., Filippi M. Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage. Hum. Brain Mapp. 2014, 35:1921-1929.
4. Ahmed I., Bose S.K., Pavese N., Ramlackhansingh A., Turkheimer F., Hotton G., Brooks D.J. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 2011, 134:979-986.
5. *Aiello M., Salvatore E., Cachia A., Pappata S., Cavaliere C., Prinster A., Quarantelli M. Relationship between simultaneously acquired resting-state regional cerebral glucose metabolism and functional MRI: a PET/MRI hybrid scanner study. Neuroimage 2015, 113:111-121.
6. Airaksinen K., Mäkelä J.P., Nurminen J., Luoma J., Taulu S., Ahonen A., Pekkonen E. Cortico-muscular coherence in advanced Parkinson's disease with deep brain stimulation. Clin. Neurophysiol. 2015, 126:748.
7. Al-Bachari S., Parkes L.M., Vidyasagar R., Hanby M.F., Tharaken V., Leroi I., Emsley H.C.A. Arterial spin labeling reveals prolonged arterial arrival time in idiopathic Parkinson's disease. Neuroimage Clin. 2014, 6:1-8.
8. Alexander A.L., Lee J.E., Lazar M., Field A.S. Diffusion tensor imaging of the brain. Neurotherapeutics 2007, 4:316-329.
9. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
10. Ali K., Morris H.R. Parkinson's disease: chameleons and mimics. Pract. Neurol. 2014, 10.1136/practneurol-2014-000849.
11. Alonso-Canovas A., Lopez-Sendon J.L., Buisan J., deFelipe-Mimbrera A., Guillan M., Garcia-Barragan N., Walter U. Sonography for diagnosis of Parkinson disease - from theory to practice. J. Ultrasound Med. 2014, 33:2069-2074.
12. Anders S., Sack B., Pohl A., Münte T., Pramstaller P., Klein C., Binkofski F. Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele. Brain 2012, 135:1128-1140.
13. Andronesi O.C., Bhat H., Reuter M., Mukherjee S., Caravan P., Rosen B.R. Whole brain mapping of water pools and molecular dynamics with rotating frame MR relaxation using gradient modulated low-power adiabatic pulses. Neuroimage 2014, 89:92-109.
14. Appel L., Jonasson M., Danfors T., Nyholm D., Askmark H., Lubberink M., Sörensen J. Use of 11C-PE21 PET in differential diagnosis of parkinsonian disorders. J. Nucl. Med. 2015, 56:234-242.
15. Aquino D., Contarino V., Albanese A., Minati L., Farina L., Grisoli M., Chiapparini L. Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol. Sci. 2014, 35:753-758.
16. Auning E., Kjaervik V.K., Selnes P., Aarsland D., Haram A., Bjørnerud A., Fladby T. White matter integrity and cognition in Parkinson's disease: a cross-sectional study. BMJ Open 2014, 4:e003976.
17. Bach M., Laun F.B., Leemans A., Tax C.M.W., Biessels G.J., Stieltjes B., Maier-Hein K.H. Methodological considerations on tract-based spatial statistics (TBSS). Neuroimage 2014, 100:358-369.
18. Bagchi D.P., Yu L., Perlmutter J.S., Xu J., Mach R.H., Tu Z., Kotzbauer P.T. Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLOS ONE 2013, 8(2):e55031. 10.1371/journal.pone.0055031.
19. Baggio H.C., Sala-Llonch R., Segura B., Marti M.-J., Valldeoriola F., Compta Y., Junque C. Functional brain networks and cognitive deficits in Parkinson's disease. Hum. Brain Mapp. 2014, 35:4620-4634.
20. **Baik K.W., Cha J., Ham J.H., Baek G.-M., Sunwoo M.K., Hong J.Y., Lee P.H. Dopaminergic modulation of resting-state functional connectivity in de novo patients with Parkinson's disease. Hum. Brain Mapp. 2014, 35:5431-5441.
21. 123I) ioflupane in diagnosis of parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry 2013, 84:1288-1295.
22. Barnes K.A., Cohen A.L., Power J.D., Nelson S.M., Dosenbach Y.B.L., Miezin F.M., Schlagger B.L. Identifying basal ganglia divisions in individuals using resting-state functional connectivity MRI. Front. Syst. Neurosci. 2010, 10.3389/fnsys.2010.00018.
23. 18F-FDG PET to medicine over 3 decades. J. Nucl. Med. 2008, 49:17N-37N.
24. **Baudrexel S., Witte T., Seifried C., Von Wegner F., Beissner F., Klein J.C., Hilker R. Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson's disease. Neuroimage 2011, 55:1728-1738.
25. *Bhidayasiri R., Chotipanich C., Joutsa J., Tepmongkol S., Wannachi N., Johansson J., Rinne J.O. Boxing and Parkinson disease: a link or a myth? An 18F-FDOP PET/CT study in retired Thai traditional boxers. Parkinsonism Relat. Disord. 2012, 18:694-696.
26. Biswal B.B., Mennes M., Zuo X.-N., Gohel S., Kelly C., Smith S.M., Milham M.P. Toward discovery science of human brain function. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4734-4739.
27. *Biundo B., Weis L., Facchini S., Formento-Dojot P., Vallelunga A., Pilleri M., Antonini A. Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. Mov. Disord. 2015, 15:688-695.
28. *Black K.J., Hershey T., Hartlein J.M., Carl J.L., Perlmutter J.S. Levodopa challenge neuroimaging of levodopa-related mood fluctuation in Parkinson's disease. Neuropsychopharmacology 2005, 30:590-601.
29. *Blazejewska A., Schwarz S.T., Pitiot A., Stephenson M.C., Lowe J., Bajaj N., Gowland P.A. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology 2013, 81:534-540.
30. Boassa D., Berlanga M.L., Yang M.-L., Terada M., Hu J., Bushong E.A., Ellisman M.H. Mapping the subcellular distribution of alpha-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis. J. Neurosci. 2013, 33:1615-2605.
31. Bohnen N.I., Müller M.L.T.M. In vivo neurochemical imaging of olfactory dysfunction in Parkinson's disease. J. Neural Transm. 2013, 120:571-576.
32. Bohnen N.I., Müller M.L.T.M., Zarzhevsky N., Koeppe R.A., Bogan C.W., Kilbourn M.R., Albin R.L. Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. Brain 2011, 134:2358-2365.
33. **Bomasang-Layno E., Fadlon I., Murray A.N., Himelhoch S. Antidepressive treatments for Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 2015, 21:833-842.
34. Borghammer P., Hansen S.B., Eggers C., Chakravarty M., Vang K., Aanerud J., Gjedde A. Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurol. Scand. 2012, 125:303-313.
35. Borroni B., Premi E., Formenti A., Turrone R., Alberici A., Cottini E., Padovani A. Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia. Parkinsonism Relat. Disord. 2015, 10.1016/j.parkreldis.2015.06.013.
36. Bortolanza M., Cavalcanti-Kiwiatkoski R., Padovan-Neto F.E., da-Silva C.A., Mitkovski M., Raisman-Vozari R., Del-Bel E. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. Neurobiol. Dis. 2015, 73:377-387.
37. Bouwmans A.E.P., Vlaar A.M.M., Mess W.H., Kessels A., Weber W.E. Specificity and sensitivity of the transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. BMJ Open 2013, 3:e002613.
38. **Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
39. Bradvica I.S., Mihaljevic I., Butkovic-Soldo S., Kadojic D., Titlic M., Bradvica M., Kralik K. Transcranial sonography and the pocket smell test in the differential diagnosis between Parkinson's disease and essential tremor. Neurol. Sci. 2015, 10.1007/s10072-015-2152-y.
40. Brooks D.J. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx 2005, 2:226-236.
41. Brooks D.J., Pavese N. Imaging biomarkers in Parkinson's disease. Prog. Neurobiol. 2011, 95:614-628.
42. **Brunenberg E.J.L., Moeskops P., Backes W., Pollo C., Cammoun L., Vilanova A., Platel B. Structural and resting state functional connectivity of the subthalamic nucleus: identification of motor STN parts and the hyperdirect pathway. PLOS ONE 2012, 7(6):e39061. 10.1371/journal.pone.0039061.
43. 18F-P3BZA PET/CT. Radiology 2014, 272:174-183.
44. Bunzeck N., Singh-Curry V., Eckart C., Weiskopf N., Perry R.J., Bain P.G., Husain M. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease. Parkinsonism Relat. Disord. 2013, 19:1136-1142.
45. Burciu R.G., Ofori E., Shukla P., Planetta P.J., Snyder A.F., Li H., Vaillancourt D.E. Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease. Mov. Disord. 2015, 10.1002/mds.26294.
46. Burke R.E., O'Malley K. Axon degeneration in Parkinson's disease. Exp. Neurol. 2013, 246:72-83.
47. Calabresi P., Castrioto A., Di Filippo M., Picconi B. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. Lancet Neurol. 2013, 12:811-821.
48. Calabresi P., Picconi B., Parnetti L., Di Filippo M.D. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol. 2006, 5:974-983.
49. **Campbell M.C., Koller J.M., Snyder A.Z., Buddhala C., Kotzbauer P.T., Perlmutter J.S. CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology 2015, 84:2413-2421.
50. Campbell M.C., Markham J., Flores H., Hartlein J.M., Goate A.M., Cairns N.J., Perlmutter J.S. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 2013, 81:520-527.
51. Carbonell F., Nagano-Saito A., Leyton M., Cisek P., Benkelfat C., He Y., Dagher A. Dopamine precursor depletion impairs structure and efficiency of resting state brain functional networks. Neuropharmacology 2014, 84:90-100.
52. Carlsson A., Waters N.W., Waters S., Carlsson M.L. Network interactions in schizophrenia - therapeutic implications. Brain Res. Interact. 2000, 31:342-349.
53. Carriere N., Lopes R., Defebvre L., Delmaire C., Dujardin K. Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease. Neurology 2015, 84:1-8.
54. *Castellanos G., Fernandez-Seara M.A., Lorenzo-Betancor O., Ortega-Cubero S., Puigvert M., Uranga J., Pastor M.A. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov. Disord. 2015, 10.1002/mds.26201.
55. Chen N.-K., Chou Y.-H., Song A.W., Madden D.J. Measurement of spontaneous signal fluctuations in fMRI: adult age differences in intrinsic functional connectivity. Brain Struct. Funct. 2009, 213:571-585.
56. Cherubini A., Morelli M., Nistico R., Salsone M., Gennarina A., Vasta R., Quattrone A. Magnetic resonance support vector machine discriminates between Parkinson disease and progressive supranuclear palsy. Mov. Disord. 2014, 29:266-269.
57. Cho Z.-L., Oh S.-H., Kim J.-M., Park S.-Y., Kwon D.-H., Jeong H.-J., Jeon B.S. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. Mov. Disord. 2011, 26:713-718.
58. Coakeley S., Strafella A.P. Imaging pathological tau in atypical parkinsonian disorders. Curr. Opin. Neurol. 2015, 28:447-452.
59. **Cochrane C.J., Ebmeier K.P. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 2013, 80:857-864.
60. Cole D.M., Beckmann C.F., Oei N.Y.I., Both S., van Gerven J.M.A., Rombouts S.A.R.B. Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity. Neuroimage 2013, 78:59-67.
61. 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage 2006, 33:423-429.
62. Criswell S.R., Perlmutter J.S., Videen T.O., Moerlein S.M., Flores H.P., Birke A.M., Racette B.A. Reduced uptake of [18F]FDOPA PET in asymptomatic welders with occupational manganese exposure. Neurology 2011, 76:1296-1301.
63. 18F]FDOPA. Psychiatry Res.: Neuroimaging 2008, 163:171-182.
64. Dager S.R., Oskin N.M., Richards T.L., Posse S. Research applications of magnetic resonance spectroscopy (MRS) to investigate psychiatric disorders. Top. Magn. Reson. Imaging 2008, 19(2):81-96. 10.1097/RMR.0b01318181e0be.
65. Dehorter N., Guigoni C., Lopez C., Hirsch J., Eusebio A., Ben-Ari Y., Hammond C. Dopamine-deprived striatal GABAergic interneurons burst and generate repetitive IPSCs in medium spiny neurons. J. Neurosci. 2009, 29:7776-7787.
66. Delong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990, 13:281-285.
67. Detre J.A., Rao H.R., Wang D.J.J., Chen Y.F., Wang Z. Applications of arterial spin labeled MRI in the brain. J. Magn. Reson. Imaging 2012, 35:1026-1037.
68. Di X., Kim E.H., Huang C.-C., Tsai S.-J., Lin C.-P., Biswal B.B. The influence of the amplitude of low-frequency fluctuations on resting-state functional connectivity. Front. Hum. Neurosci. 2013, 7:118. 10.3389/fnhum.2013.00118.
69. Di Martino A., Scheres A., Margulies D.S., Kelly A.M.C., Uddin L.Q., Shehzad Z., Milham M.P. Functional connectivity of human striatum: a resting state fMRI study. Cereb. Cortex 2008, 8:2735-2747.
70. Draganski B., Kherif F., Klöppel S., Cook P.A., Alexander D.C., Parker G.J.M., Frackowiak R.S.J. Evidence for segregated and integrative connectivity patterns in the human basal ganglia. J. Neurosci. 2008, 28:7143-7152.
71. Du C., Volkow N.D., Koretsky A.P., Pan Y. Low-frequency calcium oscillations accompany deoxyhemoglobin oscillations in rat somatosensory cortex. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(43):E4677-E4686. 10.1073/pnas.1410800111.
72. *Duncan G.W., Firbank M.J., O'Brien J.T., Burn D.J. Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?. Mov. Disord. 2013, 28:425-438.
73. 1a receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology 2008, 199:99-108.
74. Duvoisin R.C. Variations in the on-off phenomenon. Adv. Neurol. 1974, 5:339-340.
75. Düzel E., Bunzcek N., Guitart-Masip M., Wittmann B., Schott B.H., Tobler N. Functional imaging of the human dopaminergic midbrain. Trends Neurosci. 2009, 32:321-328.
76. Dydak U., Jiang Y.-M., Long L.-L., Zhu H., Chen J., Li W.M., Zheng W. In vivo measurement of brain GABA concentrations by magnetic resonance spectroscopy in smelters occupationally exposed to manganese. Environ. Health Perspect. 2011, 119:219-224.
77. Eckert T., Tang C., Ma Y., Brown N., Lin T., Frucht S., Eidelberg D. Abnormal metabolic networks in atypical parkinsonism. Mov. Disord. 2008, 23:727-733.
78. Eckert T., Van Laere K., Tang C., Lewis D.E., Edwards C., Santens P., Eidelberg D. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:496-501.
79. *Edison P., Ahmed I., Fan Z., Hinz R., Gelosa G., Chaudhuri K.R., Brooks D.J. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 2013, 38:938-949.
80. Eggers C., Schmidt A., Hagenah J., Brüggemann N., Klein J.C., Tadic V., Klein C. Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 2010, 74:1798-1805.
81. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 2009, 32:548-557.
82. Emir U.E., Tuite P.J., Öz G. Elevated pontine and putamenal GABA levels in mid-.oderate Parkinson disease detected by 7Tesla proton MRS. PLOS ONE 2012, 7(1):e30918. 10.1371/journal.pone.0030918.
83. Erro R., Picillo M., Vitale C., Amboni M., Moccia M., Longo K., Barone P. Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J. Neurol. Neurosurg. Psychiatry 2013, 84:14-17.
84. Esposito F., Tessitore A., Giordano A., De Micco R., Paccone A., Conforti R., Tedeschi G. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa. Brain 2013, 136:710-725.
85. Farquharson S., Tournier J.-T., Calamante F., Fabinyi G., Schneider-Kolsky M., Jackson G.D., Connelly A. White matter fiber tractography: why we need to move beyond DTI. J. Neurosurg. 2013, 118:1367-1377.
86. **Feigin A., Kaplitt M.G., Tang C., Lin T., Mattis P., Dhawan V., Eidelberg D. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19559-19564.
87. *Fernandez-Seara M.A., Mengual E., Vidorreta M., Castellanos G., Irigoyen J., Erro E., Pastor M.A. Resting state functional connectivity of the subthalamic nucleus in Parkinson's disease assessed using arterial spin-labeled perfusion fMRI. Hum. Brain Mapp. 2015, 36:1937-1950.
88. Fioravanti V., Benuzzi F., Codeluppi L., Contardi S., Cavallieri F., Nichelli P., Valzania F. MRI correlates of Parkinson's disease progression: a voxel based morphometry study. Parkinson's Dis. 2015, 10.1155/2015/378032.
89. Fox M.D., Snyder A.Z., Vincent J.L., Corbetta M., Van Essen D.C., Raichle M.E. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9673-9678.
90. de la Fuente-Fernandez R. Frontostriatal cognitive staging in Parkinson's disease. Parkinson's Dis. 2012, 2012:561046. 10.1155/2012/561046.
91. Galvan A., Wichmann T. Pathophysiology of Parkinsonism. Clin. Neurophysiol. 2008, 119:1459-1474.
92. Garcia-Lorenzo D., Santos C.L.-D., Ewenczyk C., Leu-Semenescu S., Gallea C., Quattrocchi G., Lehericy S. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain 2013, 136:2120-2129.
93. Garraux G., Phillips C., Schrouff J., Kreisler A., Lemaire C., Degueldre C., Salmon E. Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes. Neuroimage Clin. 2013, 2:883-893.
94. Gatto N.M., Deapen D., Stoyanoff S., Pinder R., Narayan S., Bordelon Y., Ritz B. Lifetime exposure to estrogens and Parkinson's disease in California teachers. Parkinsonism Relat. Disord. 2014, 20:1149-1156.
95. Gerasimou G., Costa D.C., Papanastasiou E., Bostanjiopoulou S., Arnaoutoglou M., Moralidis E., Gotzamani-Psarrakou A. SPECT study with I-123-Ioflupane (DaTSCAN) inpatients with essential tremor Is there any correlation with Parkinson's disease?. Ann. Nucl. Med. 2012, 26:337-344.
96. 11C-donepezil PET. Brain 2015, 138:653-663.
97. Goedert M., Spillantini M.G., Tredici K.D., Braak H. 100 years of Lewy pathology. Nat. Rev. Neurosci. 2013, 9:13-24.
98. Goldstein D.S., Holmes C., Bentho O., Sato T., Moak M.D., Sharabi Y., Eldadah B.A. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat. Disord. 2008, 14:600-607.
99. Gonzalez-Garcia N., Armony J.L., Soto J., Trejo D., Alegria M.A., Drucker-Colin Effects of rTMS on Parkinson's disease: a longitudinal fMRI study. J. Neurol. 2011, 258:1268-1280.
100. Gorges M., Müller H.-P., Lule D., Ludolph A.C., Pinkhardt E.H., Kassubek J. Functional connectivity within the default mode network is associated with saccadic accuracy in Parkinson's disease: a resting-state fMRI and videooculographic study. Brain Connect. 2013, 3:265-272.
101. Göttlich M., Münte T.F., Heldmann M., Kasten M., Hagenah J., Krämer U.M. Altered resting state brain networks in Parkinson's disease. PLOS ONE 2013, 8(10):e77336. 10.1371/journal.pone.0077336.
102. Graff-Radford J., Boeve B.F., Murray M., Ferman T.J., Tosakulwong N., Lesnick T.G., Kantarci K. Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiol. Aging 2014, 35:1483-1490.
103. Gröger A., Kolb R.K., Schäfer R., Klose U. Dopamine reduction in the substantianigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. PLOS ONE 2014, 9(1):e84081. 10.1371/journal.pone.0084081.
104. Hacker C.D., Perlmutter J.S., Criswell S.R., Ances B.M., Snyder A.Z. Resting state functional connectivity of the striatum in Parkinson's disease. Brain 2012, 135:3699-3711.
105. Hagmann P., Jonasson L., Maeder P., Thiran J.-P., Wedeen V.J., Meuli R. Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics 2006, 26:S205-S223.
106. *Haller S., Badoud S., Nguyen D., Garibotto V., Lovblad K.O., Burkhard P.R. Individual detection of patients with Parkinson disease using support vector machine analysis of diffusion tensor imaging data: initial results. Am. J. Neuroradiol. 2012, 33:2123-2128.
107. Ham J.H., Cha J., Lee J.J., Baek G.-M., Sunwoo M.K., Hong J.Y., Lee P.H. Nigrostriatal dopamine-independent resting-state functional networks in Parkinson's disease. Neuroimage 2015, 119:296-304.
108. Hammoud D.A., Hoffman J.M., Pomper M.G. Molecular neuroimaging: from conventional to emerging techniques. Radiology 2007, 245:21-42.
109. Hellwig S., Amtage F., Kreft A., Buchert R., Winz O.H., Vach W., Meyer P.T. [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012, 79:1314-1322.
110. **Hellwig S., Kreft A., Amtage F., Tüscher O., Winz O.H., Hellwig B., Meyer P.T. 123I-iodobenzamide SPECT is not an independent predictor of dopaminergic responsiveness in patients with suspected atypical Parkinsonian syndromes. J. Nucl. Med. 2013, 54:2081-2086.
111. **Helmich R.C., Derikx L.C., Bakker M., Scheeringa R., Bloem B.R., Toni I. Spatial remapping of cortico-striatal connectivity in Parkinson's disease. Cereb. Cortex 2010, 20:1175-1186.
112. Hely M.A., Reid W.G.J., Adena M.A., Halliday G.M., Morris J.G.L. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 2008, 23:837-844.
113. Henkelman R.M., Stanisz G.J., Graham S.J. Magnetization transfer in MRI: a review. NMR Biomed. 2001, 14:57-64.
114. **Herz D.M., Eickhoff S.B., Lokkegaard A., Siebner H.R. Functional neuroimaging of motor control in Parkinson's disease: a meta-analysis. Hum. Brain Mapp. 2014, 35:3227-3237.
115. Herz D.M., Haagensen B.N., Christensen M.S., Madsen K.H., Rowe J.B., Løkkegaard A., Siebner H.R. Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans. Brain 2015, 10.1093/brain/awv096.
116. Hickey P., Stacy M. Available and emerging treatments for Parkinson's disease: a review. Drug Des. Dev. Ther. 2011, 5:241-254.
117. Hilker R., Pilatus U., Eggers C., Hagenah J., Roggendorf J., Baudrexel S., Hattingen E. The bioenergetic status related to dopamine neuron loss in familial PD with PINK1 mutations. PLOS ONE 2012, 7(12):e51308. 10.1371/journal.pone.3080051.
118. **Hirano S., Asanuma K., Ma Y., Tang C., Feigin A., Dhawan V., Eidelberg D. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J. Neurosci. 2008, 28:4201-4209.
119. Höglinger G.U., Huppertz H.-J., Wagenpfeil S., Andres M.V., Belloch V., Leon T.L., del Ser T. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov. Disord. 2014, 29:479-487.
120. Holiga S., Mueller K., Möller H.E., Sieger T., Schroeter M.L., Vymazal J., Jech R. Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies. PLOS ONE 2013, 8(2):e56133. 10.1371/journal.pone.0056133.
121. **Holtbernd F., Gagnon J.-F., Postuma R.B., Ma Y., Tang C.C., Feigin A., Montplaisir J. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 2014, 82:620-627.
122. Honey G.D., Suckling J., Zelaya F., Long C., Routledge C., Jackson S., Bullmore E.T. Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system. Brain 2003, 126:1767-1781.
123. *Hou Y., Wu X., Hallett M., Chan P., Wu T. Frequency-dependent neural activity in Parkinson's disease. Hum. Brain Mapp. 2014, 35:5815-5833.
124. 18F-DTBZ positron emission tomography. JAMA Neurol. 2014, 71:758-766.
125. 18F-AV-133 PET imaging in healthy controls and Parkinson's disease patients. Nucl. Med. Biol. 2014, 41:322-329.
126. Iannaccone S., Cerami C., Alessio M., Garibotto V., Panzacchi A., Olivieri S., Perani D. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat. Disord. 2013, 19:47-52.
127. Isaias I.U., Spiegel J., Brumberg J., Cosgrove K.P., Marotta G., Oishi N., Samnick S. Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease. Front. Aging Neurosci. 2014, 6:213. 10.3389/fnagi.2014.00213.
128. Jadvar H., Colletti P.M. Competitive advantage of PET/MRI. Eur. J. Radiol. 2014, 83:84-94.
129. **Jahanshahi M., Jones C.R.G., Zijlmans J., Katsenschlager R., Lee L., Quinn N., Lees A.J. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain 2010, 133:727-745.
130. Jaunarajs K.L.E., Angoa-Perez M., Kuhn D.M., Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci. Biobehav. Rev. 2011, 35:556-564.
131. Jech R., Mueller K., Schroeter M.L., Ruzicka E. Letter to the editor: levodopa increases functional connectivity in the cerebellum and brainstem in Parkinson's disease. Brain 2013, 136:1-2.
132. Ji L., Wang Y., Zhu D., Liu W., Shi J. White matter differences between multiple system atrophy (parkinsonian type) and Parkinson's disease: a diffusion tensor image study. Neuroscience 2015, 10.1016/j.neuroscience.2015.07.060.
133. Jiminez-Urbieta H., Gago B., de la Riva P., Delgado-Alvarado M., Marin C., Rodriguez-Oroz M.C. Dyskinesias and impulse control disorders in Parkinson's disease: from pathogenesis to potential therapeutic approaches. Neurosci. Biobehav. Rev. 2015, 10.1016/j.neubiorev.07.010.
134. Joutsa J., Johansson J., Seppänen M., Noponen T., Kaasinen V. Dorsal-to-ventral shift in midbrain dopaminergic projections and increased thalamic/raphe serotonergic function in early Parkinson disease. J. Nucl. Med. 2015, 56:1036-1041.
135. **Kahan J., Urner M., Moran R., Flandin G., Marreiros A., Mancini L., Foltynie T. Resting state functional MRI in Parkinson's disease: the impact of deep brain stimulation on 'effective' connectivity. Brain 2014, 137:1130-1144.
136. Kamagata K., Motoi Y., Abe O., Shimoji K., Hori M., Nakanishi A., Sano T., Hattori N. White matter alteration of the cingulum in Parkinson disease with and without dementia: evaluation by diffusion tensor tract-specific analysis. Am. J. Neuroradiol. 2012, 33:890-895.
137. Kamagata K., Motoi Y., Tomiyama H., Abe O., Ito K., Shimoji K., Hattori N. Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis. Eur. Radiol. 2013, 23:1946-1955.
138. Kamagata K., Tomiyama H., Hatano T., Motoi Y., Abe O., Shimoji K., Aoki S. A preliminary diffusional kurtosis imaging study of Parkinson disease: comparison with conventional diffusion tensor imaging. Neuroradiology 2014, 56:251-258.
139. Kantarci K., Lowe V.J., Boeve B.F., Weigand S.D., Senjems M.L., Przybelski S.A., Jack C.R. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol. Aging 2012, 33:2091-2105.
140. Kapogiannis D., Reiter D.A., Willette A.A., Mattson M.P. Posteromedial cortex glutamate and GABA predict intrinsic functional connectivity of the default mode network. Neuroimage 2013, 64:112-119.
141. Kas A., Bottlaender M., Gallezot J.D., Vidailhet M., Villafane G., Gregoire M.C., Remy P. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J. Cereb. Blood Flow Metab. 2009, 29:1601-1608.
142. Kelly C., de Zubicaray G., Di Martino A., Copland D.A., Reiss P.T., Klein D.F., McMahon K. l-DOPA modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study. J. Neurosci. 2009, 29:7364-7378.
143. Kepe V., Bordelon Y., Boxer A., Huang S.C., Liu J., Thiede F.C., Barrio J.R. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J. Alzheimers Dis. 2013, 36:145-153.
144. Kiessling F. Science to practice: cellular therapy of Parkinson disease - a new radiotracer to target transplanted dopaminergic cells with PET. Radiology 2014, 272:1-3.
145. Kim D.-J., Park B., Park H.-J. Functional connectivity-based identification of subdivisions of the basal ganglia and thalamus using multilevel independent component analysis of resting state fMRI. Hum. Brain Mapp. 2013, 34:1371-1385.
146. Kim H.J., Kim S.J., Kim H.S., Choi C.G., Kim N., Han S., Lee C.S. Alterations of mean diffusivity in brain white matter and deep gray matter in Parkinson's disease. Neurosci. Lett. 2013, 550:64-68.
147. Kim Y.-H., Ma H.-I., Kim Y.J. Utility of the midbrain tegmentum diameter in the differential diagnosis of progressive supranuclear palsy from idiopathic Parkinson's disease. J. Clin. Neurol. 2015, 11:268-274.
148. Klein C., Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med. 2012, 2:a008888. 10.1101/cshperspect.a008888.
149. **Ko J.H., Feigin A., Mattis P.J., Tang C.C., Ma Y., Dhawan V., Eidelberg D. Network modulation following sham surgery in Parkinson's disease. J. Clin. Investig. 2014, 124:3656-3666.
150. Ko J.H., Mure H., Tang C.C., Ma Y., Dhawan V., Spetsieris P., Eidelberg D. Parkinson's disease: increased motor network activity in the absence of movement. J. Neurosci. 2013, 33:4540-4549.
151. Kotagal V., Albin R.L., Müller M.L.T.M., Koeppe R.A., Chervin R.D., Frey K.A., Bohnen N.I. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann. Neurol. 2012, 71:560-568.
152. Kwak Y., Peltier S., Bohnen N.I., Müller M.L.T.M., Dayalu P., Seidler R.D. Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson's disease. Front. Syst. Neurosci. 2010, 4:143. 10.3389/fnsys.2010.00143.
153. Kwak Y., Peltier S., Bohnen N.I., Müller M.L.T.M., Dayalu P., Seidler R.D. l-DOPA changes spontaneous low-frequency BOLD signal oscillations in Parkinson's disease: a resting state fMRI study. Front. Syst. Neurosci. 2012, 6:52. 10.3389/fnsys.2012.00052.
154. Kwon H.G., Jang S.H. Differences in neural connectivity between substantia nigra and ventral tegmental area in the human brain. Front. Hum. Neurosci. 2014, 8:41. 10.3389/fnhum.2014.00041.
155. Laere K.V., Casteels C., Lunskens S., Goffin K., Grachev I.D., Bormans G., Vandenberghe W. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol. Aging 2012, 33(3). 620.e1-620.e8.
156. Lanciego J.L., Luquin N., Obeso J.A. Functional neuroanatomy of the basal ganglia. Cold Spring Harb. Perspect. Med. 2012, 2(12):a009621.
157. Langston J.W. The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann. Neurol. 2006, 59:591-596.
158. Le Bihan D.L. Looking into the functional architecture of the brain with diffusion MRI. Nat. Rev. Neurosci. 2003, 4:469-480.
159. Lebedev A.V., Westman E., Simmons A., Lebedeva A., Siepel F.J., Pereira J.B., Aarsland D. Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. Front. Syst. Neurosci. 2014, 8:45. 10.3389/fnsys.2014.00045.
160. Lee E.-Y., Eslinger P.J., Guangwei D., Kong L., Lewis M.M., Huang X. Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson's disease. Mov. Disord. 2014, 29:1205-1208.
161. Lee J.E., Cho K.H., Ham J.H., Song S.K., Sohn Y.H., Lee P.H. Olfactory performance acts as a cognitive reserve in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 2014, 20:186-191.
162. Lee J.-Y., Seo S.H., Kim Y.K., Yoo H.B., Kim Y.E., Song I.C., Jeon B.S. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. J. Neurol. Neurosurg. Psychiatry 2014, 85:23-30.
163. *Lee P.H., Lee J.E., Kim H.-S., Song S.K., Lee H.S., Nam H.S., Sohn Y.H. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann. Neurol. 2012, 72:32-40.
164. Lees A.J. The on-off phenomenon. J. Neurol. Neurosurg. Psychiatry 1989, 52(Suppl.):29-37.
165. Lemke M.R. Depressive symptoms in Parkinson's disease. Eur. J. Neurol. 2008, 15(Suppl. 1):21-25.
166. **Lenglet C., Abosch A., Yacoub E., De Martino F., Sapiro G., Harel N. Comprehensive in vivo mapping of the human basal ganglia and thalamic connectome in individuals using 7T MRI. PLOS ONE 2012, 7(1):e29153. 10.1371/journal.pone.0029153.
167. Lenka A., Jhunjhunwala K.R., Saini J., Pal P.K. Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: a critical review. Parkinsonism Relat. Disord. 2015, 10.1016/j.parkreldis.2015.04.005.
168. Levesque M., Parent A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11888-11893.
169. Levin B.E., Katzen H.L., Maudsley A., Post J., Myerson C., Govind V., Mittel A. Whole-brain proton MR spectroscopic imaging in Parkinson's disease. J. Neuroimaging 2012, 24:39-44.
170. Lewis S.J., Pavese N., Rivero-Bosch M., Eggert K., Oertel W., Mathias C.J., Gerhard A. Brain monoamine systems in multiple system atrophy: a positron emission tomography study. Neurobiol. Dis. 2012, 46:130-136.
171. LeWitt P.A. Norepinephrine: the next therapeutics frontier for Parkinson's disease. Transl. Neurodegen. 2012, 1:4. 10.1186/2047-9158-1-4.
172. Liang Z., King J., Zhang N. Anticorrelated resting-state functional connectivity in awake rat brain. Neuroimage 2011, 592:1190-1199.
173. Lin C.H., Wu R.-M. Biomarkers of cognitive decline in Parkinson's disease. Parkinsonism Relat. Disord. 2015, 10.1016/j.parkreldis.2015.02.010.
174. Little S., Brown P. The functional role of beta oscillations in Parkinson's disease. Parkinsonism Relat. Disord. 2014, 20S1:S44-S48.
175. Liu H., Edmiston E.K., Fan G., Xu K., Zhao B., Wang F. Altered resting-state functional connectivity of the dentate nucleus in Parkinson's disease. Psychiatry Res.: Neuroimaging 2013, 211:64-71.
176. Liu T., Eskreis-Winkler S., Schweitzer A.D., Chen W., Kaplitt M.G., Tsiouris A.J., Wang Y. Improved subthalamic nucleus depiction with quantitative susceptibility mapping. Radiology 2013, 269:216-223.
177. *Loftipour A.K., Wharton S., Schwarz S.T., Gontu V., Schäfer A., Peters A.M., Bajaj N.P.S. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J. Magn. Reson. Med. 2012, 35:48-55.
178. Logothetis N.K. What we can do and what we cannot do with fMRI. Nature 2008, 453:869-878.
179. Long D., Wang J., Xuan M., Gu Q., Xu X., Kong D., Zhang M. Automatic classification of Parkinson's disease with multi-modal MR imaging. PLOS ONE 2012, 7(11):e47714. 10.1371/journal.pone.0047714.
180. Lubomski M., Rushworth R.L., Lee W., Bertram K., Williams D.R. Sex differences in Parkinson's disease. J. Clin. Neurosci. 2014, 21:1503-1506.
181. **Lucero C., Campbell M., Flores H., Maiti B., Perlmutter J.S., Foster E.R. Cognitive reserve and β-amyloid pathology in Parkinson disease. Parkinsonism Relat. Disord. 2015, 21:899-904.
182. Luo C.-Y., Chen Q., Song Q., Chen K., Guo X.-Y., Yang J., Shang H.-F. Resting-state fMRI study on drug-naive patients with Parkinson's disease and with depression. J. Neurol. Neurosurg. Psychiatry 2014, 85:675-683.
183. Luo C.-Y., Song W., Chen Q., Zheng Z.-Z., Chen K., Cao B., Shang H.-F. Reduced functional connectivity in early-stage drug naive Parkinson's disease: a resting-state fMRI study. Neurobiol. Aging 2014, 35:431-441.
184. Ma Y., Huang C., Dyke J.P., Pan H., Alsop D., Feigin A., Eidelberg D. Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J. Cereb. Blood Flow Metab. 2010, 30:505-509.
185. Ma Y., Peng S., Spetsieris P.G., Sossi V., Eidelberg D., Doudet D.J. Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. J. Cereb. Blood Flow Metab. 2012, 32:633-642.
186. 18F-DOPA PET outcomes. J. Nucl. Med. 2010, 51:7-15.
187. *Ma Y., Tang C., Spetsieris P.G., Dhawan V., Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J. Cereb. Blood Flow Metab. 2007, 27:597-605.
188. **MacDonald P.A., MacDonald A.A., Seergobin K.N., Tamjeedi R., Ganjavi H., Provost J.-S., Monchi O. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. Brain 2011, 134:1447-1463.
189. Madden D.J., Bennett I.J., Burzynska A., Potter G., Chen N.-K., Song A.W. Diffusion tensor imaging of cerebral white matter integrity in cognitive aging. Biochim. Biophys. Acta 2012, 1822:386-400.
190. Madhyastha T.M., Askren M.K., Boord P., Zhang J., Leverenz J.B., Grabowski T.J. Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease. Mov. Disord. 2015, 10.1002/mds.26128.
191. Mak E., Su L., Williams G.B., O'Brien J.T. Neuroimaging correlates of cognitive impairment and dementia in Parkinson's disease. Parkinsonism Relat. Disord. 2015, 21:862-870.
192. Marreiros A.C., Cagnan H., Moran R.J., Friston K.J., Brown P. Basal ganglia-cortical interactions in Parkinsonian patients. Neuroimage 2013, 66:301-310.
193. Mattis P.J., Tang C.C., Ma Y., Dhawan V., Edidelberg D. Network correlates of the cognitive response to levodopa in Parkinson's disease. Neurology 2011, 77:858-865.
194. **Mayer G., Bitterlich M., Kuwert T., Ritt P., Stefan H. Ictal SPECT in patients with rapid eye movement sleep behaviour disorder. Brain 2015, 138:1263-1270.
195. Mazere J., Meissner W.G., Mayo W., Sibon I., Lamare F., Guilloteau D., Allard M. Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter. Radiology 2012, 265:537-543.
196. McCarthy M.M., Moore-Kochlacs C., Gu X., Boyden E.S., Han X., Kopell N. Striatal origin of the pathologic beta oscillations in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11620-11625.
197. **McNeill A., Wu R.-M., Tzen K.-Y., Aguiar P.C., Arbelo J.M., Barone P., Schapira A.H.V. Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. PLOS ONE 2013, 8(7):e69190. 10.1371/journal.pone.0069190.
198. Mehnert S., Reuter I., Schepp K., Maaser P., Stolz E., Kaps M. Transcranial sonography for diagnosis of Parkinson's disease. BMC Neurol. 2010, 10:9.
199. Melzer T.R., Watts R., MacAskill M.R., Pearson J.F., Rüeger S., Pitcher T.L., Anderson T.J. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain 2011, 134:845-855.
200. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn. Mem. 2004, 11:43-49.
201. Meyer P.M., Strecker K., Kendziorra K., Bevcker G., Hesse S., Woelpl D., Schwarz J. Reduced α4β2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch. Gen. Psychiatry 2009, 66:866-877.
202. Meyer-Lindenberg A. From maps to mechanisms through neuroimaging of schizophrenia. Nature 2010, 468:194-202.
203. *Miller D.B., O'Callaghan J.P. Biomarkers of Parkinson's disease: present and future. Metabolism 2015, 64:S40-S46.
204. Mishina M., Ishiwata K., Naganawa M., Kimura Y., Kitamura S., Suzuki M., Ishii K. Adenosine A2A receptors measured with [11C]TMSX PET in the striata of Parkinson's disease patients. PLoS ONE 2011, 6(2):e17338. 10.1371/journal/pone.0017338.
205. Moran R.J., Mallet N., Litvak V., Dolan R.J., Magill P.J., Friston K.J., Brown P. Alterations in brain connectivity underlying beta oscillations in Parkinsonism. PLoS Comput. Biol. 2011, 7(8):e1002124. 10.1371/journal.pcbi.1002124.
206. Morelli M., Arabia G., Messina D., Vescio B., Salsone M., Chiriaco C., Quattrone A. Effect of aging on magnetic resonance measures differentiating progressive supranuclear palsy from Parkinson's disease. Mov. Disord. 2014, 29:488-495.
207. Müller M.L.T.M., Bohnen N.I. Cholinergic dysfunction in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 2013, 139:377.
208. Murakami Y., Kakeda S., Watanabe K., Ueda I., Ogasawara A., Moriya J., Korogi Y. Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease. Am. J. Neuroradiol. 2015, 10.3174.ajnr.A4260.
209. Mure H., Hirano S., Tang C.C., Isaias I., Antonini A., Ma Y., Edielberg D. Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage 2011, 54:1244-1253.
210. **Mure H., Tang C.C., Argyelan M., Ghilardi M.-F., Kaplitt M.G., Dhawan V., Eidelberg D. Improved sequence learning with subthalamic nucleus deep brain stimulation: evidence for treatment-specific network modulation. J. Neurosci. 2012, 32:2804-2813.
211. Narayanan N.S., Rodnitzky R.L., Uc E. Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Rev. Neurosci. 2013, 24:267-278. 10.1515/revneuro-2013-0004.
212. *New A.B., Robin D.A., Parkinson A.L., Eickhoff C.R., Reetz K., Hoffstaedter F., Eickhoff S.B. The intrinsic resting state voice network in Parkinson's disease. Hum. Brain Mapp. 2015, 36:1951-1962.
213. Niethammer M., Feigin A., Eidelberg D. Functional neuroimaging in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2012, 2:a009274.
214. Niethammer M., Tang C.C., Ma Y., Mattis P.J., Ko J.H., Dhawan V., Eidelberg D. Parkinson's disease cognitive network correlates with caudate dopamine. Neuroimage 2013, 78:204-209.
215. O'Callaghan C., Bertoux M., Hornberger M. Beyond and below the cortex: the contribution of striatal dysfunction to cognition and behaviour in neurodegeneration. J. Neurol. Neurosurg. Psychiatry 2014, 85:371-378.
216. Oh M., Kim J.S., Kim J.Y., Shin K.-H., Park S.H., Kim H.O., Lee C.S. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J. Nucl. Med. 2012, 53:399-406.
217. Olde Dubbelink K.T.E., Hilllebrand A., Stoffers D., Berend Deijen J., Twisk J.R., Stam C.J., Berendse H.W. Disrupted brain network topology in Parkinson's disease: a longitudinal magnetoencephalography study. Brain 2014, 137:197-207.
218. Olde Dubbelink K.T.E., Hilllebrand A., Twisk J.W., Deijen J.B., Stoffers D., Schmand, Berendse H.W. Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers. Neurology 2014, 82:263-270.
219. Olde Dubblelink K.T.E., Stoffers D., Deijen J.B., Twisk J.W.R., Stam C.J., Hillebrand A., Berendse H.W. Resting-state functional connectivity as a marker of disease progression in Parkinson's disease: a longitudinal MEG study. Neuroimage Clin. 2013, 2:612-619.
220. 123I]FP-CIT SPECT binding potential images, using the voxels-as-features approach and support vector machines. J. Neural Eng. 2015, 12. 10.1088/1741-2560/12/2/026008.
221. O'Sullivan S.S., Williams D.R., Gallagher D.A., Massey L.A., Silveira-Moriyama L., Lees A. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov. Disord. 2008, 23:101-106.
222. Pahapill P.A., Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 2000, 123:1767-1783.
223. Palmer S.J., Li J., Wang Z.J., McKeown M.J. Joint amplitude and connectivity compensatory mechanisms in Parkinson's disease. Neuroscience 2010, 166:1110-1118.
224. 18F]FP-CIT PET/CT. Nucl. Med. Mol. Imaging 2014, 48:106-113.
225. Pavese N., Moore R.Y., Scherfler C., Khan N.L., Hotton G., Quinn N.P., Piccini P. In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp. Neurol. 2010, 222:120-124.
226. 18F-dopa PET study. Neuroimage 2011, 56:1463-1468.
227. 11C]DASB PET study in Parkinson's disease. Neuroimage 2012, 59:1080-1084.
228. Perlmutter J.S., Norris S.A. Neuroimaging biomarkers for Parkinson disease: facts and fantasy. Ann. Neurol. 2014, 76:769-783.
229. Peterson D.S., Fling B.W., Mancini M., Cohen R.G., Nutt J.G., Horak F.B. Dual-task interference and brain structural connectivity in people with Parkinson's disease who freeze. J. Neurol. Neurosurg. Psychiatry 2015, 86:786-792.
230. Petrou M., Dwamena B.A., Foerster B.R., MacEachern M.P., Bohnen N.I., Müller M.L.T.M., Frey K.A. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov. Disord. 2015, 10.1002/mds.26191.
231. Picillo M., Erro R., Amboni M., Longo K., Vitale C., Moccia M., Pellecchia M.T. Gender differences in non-motor symptoms in early Parkinson's disease: a 2-years follow-up study on previously untreated patients. Parkinsonism Relat. Disord. 2014, 20:850-854.
232. *Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat. Rev. Neurol. 2014, 10:708-722.
233. **Politis M., Wu K., Loane C., Brooks D.J., Kiferle L., Turkheimer F.E., Piccini P. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J. Clin. Investig. 2014, 124:1340-1349.
234. **Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Oertel W.H., Piccini P. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci. Transl. Med. 2012, 4:128ra41. 10.1126/scitranslmed.3003391.
235. Ponsen M.M., Stam C.J., Bosboom J.L.W., Berendse H.W., Hillebrand A. A three dimensional anatomical view of oscillatory resting-state activity and functional connectivity in Parkinson's disease related dementia: an MEG study using atlas-based beamforming. Neuroimage: Clin. 2013, 2:95-102.
236. Posse S., Otazo R., Dager S.R., Alger J. MR spectroscopic imaging: principles and recent advances. J. Magn. Reson. Imaging 2013, 37:1301-1325.
237. Poston K.L., Tang C.C., Eckert T., Dhawan V., Frucht S., Vonsattel J.-P., Eidelberg D. Network correlates of disease severity in multiple system atrophy. Neurology 2012, 78:1237-1244.
238. **Postuma R.B., Dagher A. Basal ganglia functional connectivity based on meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. Cereb. Cortex 2006, 16:1508-1521.
239. Price J.C. Molecular brain imaging in the multimodality era. J. Cereb. Blood Flow Metab. 2012, 32:1377-1392.
240. Prodoehl J., Li H., Planetta P.J., Goetz C., Shannon K.M., Tangonan R., Vaillancourt D.E. Diffusion tensor imaging of Parkinson's disease, atypical Parkinsonism, and essential tremor. Mov. Disord. 2013, 28:1816-1822.
241. **Putcha D., Ross R.S., Cronin-Golomb A., Janes A.C., Stern C.E. Altered intrinsic functional coupling between core neurocognitive networks in Parkinson's disease. Neuroimage: Clin. 2015, 7:449-455.
242. Pyatigorskaya N., Gallea C., Garcia-Lorenzo D., Vidailhet M., Lehericy S. A review of the use of magnetic resonance imaging in Parkinson's disease. Ther. Adv. Neurol. Disord. 2014, 7:206-220.
243. Qamhawi Z., Towey D., Shah B., Pagano G., Seibyl J., Marek K., Pavese N. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain 2015, 10.1093/brain/awv215.
244. Rae C.L., Correia M.M., Altena E., Hughes L.E., Barker R.A., Rowe J.B. White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage 2012, 62:1675-1684.
245. Raichle M.E. The restless brain. Brain Connect. 2011, 1:3-12. 10.10189/brain.2011.0019.
246. Ramlackhansingh A.F., Bose S.K., Ahmed I., Turkheimer F.E., Pavese N., Brooks D.J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76:1811-1816.
247. Rice M.E., Patel J.C., Cragg S.J. Dopamine release in the basal ganglia. Neuroscience 2011, 198:112-137.
248. Riedl V., Bienkowska K., Strobel C., Tahmasian M., Grimmer T., Förster S., Drzezga A. Local activity determines functional connectivity in the resting human brain: a simultaneous FDG-PET/fMRI study. J. Neurosci. 2014, 34:6260-6266.
249. Russo S.J., Nestler E.J. The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 2013, 14:609-625.
250. Sahuquillo P., Tembl J.I., Parkhutik V., Vazquez J.F., Sastre I., Lago A. The study of deep brain structures by transcranial duplex sonography and imaging resonance correlation. Ultrasound Med. Biol. 2013, 39:226-232.
251. Salvatore C., Cerasa A., Castiglioni I., Gallivanone F., Augimeri A., Lopez M., Quattrone A. Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and progressive supranuclear palsy. J. Neurosci. Methods 2014, 222:230-237.
252. *Schapira A.H.V. Recent developments in biomarkers in Parkinson disease. Curr. Opin. Neurol. 2013, 26:395-400.
253. Schapira A.H.V., Tolosa E. Molecular and clinical prodrome of Parkinson disease; implications for treatment. Nat. Rev. Neurol. 2010, 6:309-317.
254. **Scherfler C., Esterhammer R., Nocker M., Mahlknecht P., Stockner H., Warwitz B., Sepi K. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. Brain 2013, 136:3028-3037.
255. **Schwarz S.T., Abaei M., Gontu V., Morgan P.S., Baiai N., Auer D.P. Diffusion tensor imaging of nigral degeneration in Parkinson's disease: a region-of-interest and voxel-based study at 3T and systematic review with meta-analysis. Neuroimage: Clin. 2013, 3:481-488.
256. Schwarz S.T., Afzal M., Morgan P.S., Bajaj N., Gowland P.A., Auer D.P. The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case control and retrospective cross-sectional MRI study at 3T. PLOS ONE 2014, 9(4):e93814. 10.1371/journal.pone.0093814.
257. Sharma S., Moon C.S., Khogali A., Haidous A., Chabenne A., Ojo C., Ebadi M. Biomarkers in Parkinson's disease (recent update). Neurochem. Int. 2013, 63:201-229.
258. **Sharman M., Valabregue R., Perlbarg V., Marrakchi-Kacem L., Vidailhet M., Benali H., Lehericy S. Parkinson's disease patients show reduced cortical-subcortical sensorimotor connectivity. Mov. Disord. 2013, 28:447-454.
259. Sheng K., Fang W., Su M., Li R., Zou D., Han Y., Cheng O. Altered spontaneous brain activity in patients with Parkinson's disease accompanied by depressive symptoms, as revealed by regional homogeneity and functional connectivity in the prefrontal-limbic system. PLOS ONE 2014, 9(1):e84705. 10.1371/journal.pone.0084705.
260. Shine J.M., Halliday G.M., Gilat M., Matar E., Bolitho S.J., Carlos M., Lewis S.J. The role of dysfunctional attentional networks in visual misperceptions in Parkinson's disease. Hum. Brain Mapp. 2014, 35:2206-2219.
261. Shine J.M., Mata E., Ward P.B., Bolitho S.J., Pearson M., Naismith S.L., Lewis S.J.G. Differential neural activation patterns in patients with Parkinson's disease and freezing of gait in response to concurrent cognitive and motor load. PLOS ONE 2013, 8(1):e52602. 10.1371/journal.pone.0052602.
262. Siebert T.M., Murphy E.A., Kaestner E.J., Brewer J.B. Interregional correlations in Parkinson disease and Parkinson-related dementia. Radiology 2012, 263:226-234.
263. Siegel A., Sapru H.N. Essential Neuroscience 2006, Lippincott Williams & Wilkins, Philadelphia.
264. Skidmore F., Korenkevych D., Liu Y., He G., Bullmore E., Pardalos P.M. Connectivity brain networks based on wavelet correlation analysis in Parkinson fMRI data. Neurosci. Lett. 2011, 499:47-51.
265. Skidmore F.M., Yang M., Baxter L., Deneen K.M., von Collingwood J., He G., Liu Y. Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease. Neuroimage 2013, 75:249-261.
266. Skidmore F.M., Yang M., Deneen K., von, Collingwood J., He G., Tandon R., Liu Y. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. Neuroimage 2013, 81:484-495.
267. Smith Y., Wichmann T., Factor S.A., DeLong M.R. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 2012, 37:213-246.
268. **Smith R., Wu K., Hart T., Loane C., Brooks D.J., Björklund A., Politis M. The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiol. Aging 2015, 36:1736-1742.
269. Song I.-U., Chung Y.-A., Oh J.-K., Chung S.-W. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease. Acta Radiol. 2014, 55:366-371.
270. Stagg C.J., Bachtiar V., Amadi U., Gudberg C.A., Ilie A.S., Sampaio-Baptista C., Johansen-berg H. Local GABA concentration is related to network-level resting functional connectivity. eLife 2014, 3:e01465. 10.7554/eLife.01465.
271. Stam C.J. Use of magnetoencephalography (MEG) to study the functional brain networks in neurodegenerative disorders. J. Neurol. Sci. 2010, 289:128-134.
272. Stamelou M., Hoeglinger G.U. Atypical parkinsonism: an update. Curr. Opin. Neurol. 2013, 26:401-405.
273. Stoessl A.J. Imaging in Parkinson's disease: time to look below the neck. Brain 2015, 138:512-514.
274. Su M., Wang S., Weidong F., Zhu Y., Li R., Sheng K., Cheng O. Alterations in the limbic/paralimbic cortices of Parkinson's disease patients with hyposmia under resting-state functional MRI by regional homogeneity and functional connectivity analysis. Parkinsonism Relat. Disord. 2015, 21:698-703.
275. Sulzer D., Surmeier D.J. Neuronal vulnerability, pathogenesis and Parkinson's disease. Mov. Disord. 2013, 28:41-50.
276. Surdhar I., Gee M., Bouchard T., Coupland N., Malykhin N., Camicioli R. Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms. Parkinsonism Relat. Disord. 2012, 18:809-813.
277. Surmeier D.J., Sulzer D. The pathology roadmap in Parkinson disease. Prion 2013, 7:85-91.
278. Suwijn S., van Boheemen C.J.M., de Haan R., Tissingh G., Booij J., de Bie R.M.A. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: A systematic review. EJNMMI 2015, 2015(5):12. 10.1186/s13550-015-0087-1.
279. Sweet J.A., Walter B.L., Gunalan K., Chaturvedi A., McIntyre C.C., Miller J.P. Fiber tractography of the axonal pathways linking the basal ganglia and cerebellum in Parkinson disease: implications for targeting in deep brain stimulation. J. Neurosurg. 2014, 120:988-996.
280. Sydoff M., Lizana H., Mattson S., Stabin M., Leide-Svegborn S. Determination of the biodistribution and dosimetry of 123I-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT/CT imaging. Appl. Radiat. Isot. 2013, 82:300-307.
281. **Szewczyk-krolikowski K., Menke R.A.L., Rolinski M., Duff E., Salimi-Khorshidi G., Filippini N., Mackay C.E. Functional connectivity in the basal ganglia network differentiates PD patients from controls. Neurology 2015, 83:208-214.
282. Tabbal S.D., Tian L.L., Karimi M., Brown C.A., Loftin S.K., Perlmutter J.S. Low nigrostriatal reserve for motor parkinsonism in nonhuman primates. Exp. Neurol. 2012, 237:355-362.
283. Tambasco N., Nigro P., Romoli M., Simoni S., Parnetti L., Calabresi P. Magnetization transfer MRI in dementia disorders Huntington's disease and parkinsonism. J. Neurol. Sci. 2015, 353:1-8.
284. **Tang C.C., Poston K.L., Eckert T., Feigin A., Frucht A., Guidesblatt M., Eidelberg D. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010, 9:149-158.
285. Tessitore A., Amboni M., Esposito F., Russo A., Picillo M., Marcuccio L., Barone P. Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. Parkinsonism Relat. Disord. 2012, 18:781-787.
286. Tessitore A., Esposito F., Vitale C., Santangelo C., Amboni M., Russo A., Tedeschi G. Default-mode network connectivity in cognitively unimpaired patients with Parkinson's disease. Neurology 2012, 79:2226-2232.
287. Teune L.K., Renken R.J., de Jong B.M., Willemsen A.T., van Osch M.J., Roerdink J.B.T.M., Leenders K.L. Parkinson's disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging. Neuroimage: Clin. 2014, 5:240-244.
288. Teune L.K., Renken R.J., Mudali D., De Jong B.M., Dierckx R.A., Roerdink J.B.T.M., Leenders K.L. Validation of parkinsonian disease-related metabolic brain patterns. Mov. Disord. 2013, 28:547-551.
289. **Thaler A., Artzi M., Mirelman A., Jacob Y., Helmich R.C., Van Nuenen B.F.L., LRRK2 Ashkenazi Jewish Consortium A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G S LRRK2 mutation carriers. Mov. Disord. 2014, 29(2019):823-827.
290. Thiriez C., Itti E., Fenelon G., Evangelista E., Meignan M., Cesaro P., Remy P. Clinical routine use of dopamine transporter imaging in 516 consecutive patients. J. Neurol. 2015, 262:909-915.
291. Tinazzi M., Morgante F., Matinella A., Bovi T., Cannas A., Solla P., Barbui C. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Schizophr. Res. 2014, 152:344-349.
292. *Troeung L., Egan S.J., Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PLOS ONE 2013, 8(11):e79510. 10.1371/journal.pone.0079510.
293. Tuite P.J., Mangia S., Michael S. Magnetic resonance imaging (MRI) in Parkinson's disease. J. Alzheimer's Dis. Suppl. 2013, 1:001.
294. 1ρ MRI in the brainstem of Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18:623-625.
295. Tziortzi A.C., Haber S.N., Searle G.E., Tsoumpas C., Long C.J., Shotbolt P., Gunn R.N. Connectivity-based functional analysis of dopamine release in the striatum using diffusion-weighted MRI and positron emission tomography. Cereb. Cortex 2014, 24:1165-1177.
296. Van den Heuvel M.P., Hulshoff Pol H.E. Exploring the brain network: a review on resting-state fMRI functional connectivity. Eur. Neuropsychopharmacol. 2010, 20:519-534.
297. Van Mierlo T.J., Chung C., Foncke E.M., Berendse H., van den Heuvel O.A. Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume. Mov. Disord. 2015, 30:245-252.
298. Van Nuenen B.F.L., van Eimeren T., van der Vegt J.P.M., Buhmann C., Klein C., Bloem B.R., Siebner H.R. Mapping preclinical compensation in Parkinson's disease: an imaging genomics approach. Mov. Disord. 2009, 24:S703-S710.
299. Vercruysse S., Leunissen I., Vervoort G., Vandenberghe W., Swinnen S., Nieuwboer A. Microstructural changes in white matter associated with freezing of gait in Parkinson's disease. Mov. Disord. 2015, 30:567-576.
300. Vernon A.C., Ballard C., Modo M. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible?. Brain Res. Rev. 2010, 65:28-55.
301. Villemagne V.L., Okamura N. In vivo tau imaging: Obstacles and progress. Alzheimer's Dementia 2014, 10:S254-S264.
302. Vriend C., Pattij T., van der Werf Y.D., Voorn P., Booij J., Rutten S., van den Heuvel O.A. Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?. Neurosci. Biobehav. Rev. 2014, 38:60-71.
303. 123I]FP-CIT binding in the caudate nucleus. J. Neurol. Neurosurg. Psychiatry 2014, 85:159-164.
304. Wakana S., Jiang H., Nagae-Poetscher L.M., van Zijl P.C.M., Mori S. Fiber tract-based atlas of human white matter anatomy. Radiology 2004, 230:77-87.
305. *Weiduschat N., Mao X., Beal M.F., Nirenberg M.J., Shungu D.C., Henchcliffe C. Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism Relat. Disord. 2014, 20:545-548.
306. **Weintraub D., Dietz N., Duda J.E., Wolk D.A., Doshi J., Xie S.X., Siderow A. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 2012, 135:170-180.
307. Weintraub D., Papay K., Siderowf A. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 2013, 80:176-180. 10.1212/WNL.0b013e31827b915c.
308. Weiss P.H., Herzog J., Pötter-Nerger M., Falk D., Herzog H., Deuschl G., Fink G.R. Subthalamic nucleus stimulation improves parkinsonian gait via brainstem locomotor centers. Mov. Disord. 2015, 10.1002/mds.26229.
309. Wen X., Wu X., Liu J., Li K., Yao L. Abnormal baseline brain activity in non-depressed Parkinson's disease and depressed Parkinson's disease: a resting-state functional magnetic resonance imaging study. PLOS ONE 2013, 8(5):e63691. 10.1371/journal.pone.0063691.
310. Werner P., Barthel H., Drzezga A., Sabri O. Current status and future role of brain PET/MRI in clinical and research settings. Eur. J. Nucl. Med. Mol. Imaging 2015, 42:512-526.
311. Wichmann T., Dostrovsky J.O. Pathological basal ganglia activity in movement disorders. Neuroscience 2011, 198:232-244.
312. **Wing Y., Lam S.P., Zhang J., Leung E., Ho C.L., Chen S., Ho C.K.W. Reduced striatal dopamine transmission in REM sleep behavior disorder comorbid with depression. Neurology 2015, 84:516-522.
313. Wu P., Yu H., Peng S., Dauvilliers Y., Wang J., Ge J., Zuo C. Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain 2014, 137:3122-3128.
314. Wu T., Hallett M. The cerebellum in Parkinson's disease. Brain 2013, 136:696-709.
315. Wu T., Long X., Wang L., Hallett M., Zang Y., Li K., Chan P. Functional connectivity of cortical motor areas in the resting state in Parkinson's disease. Hum. Brain Mapp. 2011, 32:1443-1457.
316. Wu T., Long X., Zang Y., Wang L., Hallett M., Li K., Chan P. Regional homogeneity changes in patients with Parkinson's disease. Hum. Brain Mapp. 2009, 30:1502-1510.
317. **Wu T., Ma Y., Zheng Z., Peng S., Wu X., Eidelberg D., Chan P. Parkinson's disease-related spatial covariance pattern identified with resting-state functional MRI. J. Cereb. Blood Flow Metab. 2015, 10.1038/jcbfm.2015.118.
318. Wu T., Wang L., Hallett M., Chen Y., Li K., Chan P. Effective connectivity of brain networks during self-initiated movement in Parkinson's disease. Neuroimage 2011, 55:204-215.
319. Wu T., Wang C., Wang J., Hallett M., Zang Y., Chan P. Preclinical and clinical neural network changes in SCA2 parkinsonism. Parkinsonism Relat. Disord. 2013, 19:158-164.
320. Wu T., Wang J., Wang C., Hallett M., Zang Y., Wu X., Chan P. Basal ganglia circuits in Parkinson's disease patients. Neurosci. Lett. 2012, 524:55-59.
321. Yao N., Cheung C., Pang S., Chang R.S.-K., Lau K.K., Suckling J., McAlonan G.M. Multimodal MRI of the hippocampus in Parkinson's disease with visual hallucinations. Brain Struct. Funct. 2014, 10.1007/s00429-014-0907-5.
322. Yao N., Pang S., Cheung C., Shek-kwan C., Lau K.K., Suckling J., Chua S.-E. Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations. Parkinsonism Relat. Disord. 2015, 21:131-137.
323. **Yarnall A.J., Breen D.P., Duncan D.P., Khoo T.K., Coleman S.Y., Firbank M.J., Burn D.J. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014, 82:308-316.
324. 18F-flurodeoxyglucose positron emission tomography. Neurosci. Lett. 2015, 584:296-301.
325. **Yu F., Barron D.S., Tantiwongkosi B., Fox P. Patterns of gray matter atrophy in atypical parkinsonism syndromes: aVBM meta-analysis. Brain Behav. 2015, 10.1002/brb3.329.
326. Yu R., Liu B., Wang L., Chen J., Liu X. Enhanced functional connectivity between putamen and supplementary motor area in Parkinson's disease patients. PLOS ONE 2013, 8(3):e59717. 10.1371/journal.pone.0059717.
327. Zhang J., Bi W., Zhang Y., Zhu M., Zhang Y., Feng H., Jiang T. Abnormal functional connectivity density in Parkinson's disease. Behav. Brain Res. 2015, 280:113-118.
328. Zhang J., Wei L., Hu X., Zhang Y., Zhou D., Li C., Wang J. Specific frequency band of amplitude low-frequency fluctuation predicts Parkinson's disease. Behav. Brain Res. 2013, 252:18-23.
329. Zhang L., Liu J. The role of neuroimaging in the diagnosis of Parkinson's disease. Int. J. Integ. Med. 2013, 1(11):2013.
330. 18[F]-FDG PET study on the Idiopathic Parkinson's. disease from several parkinsonian-plus syndromes. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1):S60-S62.
331. Zheng Z., Shemmassian S., Wijekoon C., Kim W., Bookheimer S.Y., Pourtian N. DTI correlates of distinct cognitive impairments in Parkinson's disease. Hum. Brain Mapp. 2014, 35:1325-1333.